Award Data

In Phase I MER demonstrated the superior performance and power-to-weight ratios of the VS-Rotary engine. In Phase II MER will team with the University of Arizona who will provide engine modeling, simulation, and analysis along with advanced precision machining and fabrication. MER will also team with NCE of Tucson to provide test and systems integration development of the engine to the applicatio ...

As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with p ...

With the advanced capabilities planned by the TALOS program comes the risk of the operator becoming overwhelmed by the information available and the operation of the suit itself. To effectively employ the suit in the field, TALOS requires an effective situational awareness display and an intuitive, low-impact way of interacting with the suits physical/sensor systems. SoarTech proposes to continue ...

A critical aspect of exoskeleton control that has to date introduced a performance limitation is the ability of the exoskeleton to recognize the intent of the operator so it can apply assistance to their desired motion. This intent recognition effort is typically solved using ad-hoc methods where subject matter experts make design decisions and tune transitions to identify intended maneuvers as re ...

A new dual pump hydraulic supply designed to enable energetically autonomous exoskeleton robots will be developed, tested and demonstrated. This new hydraulic supply will be integrated with a high performance hydraulically actuated full body exoskeleton robot and used to test and demonstrate the overall performances of such systems. New control policies that include: (i) an assist mode, where the ...

The S-351 mini-sub is a prototype of the Dry Combat Submersible (DCS). This prototype was established as a means of risk reduction prior to a full commitment to the DCS program. Both of these platforms have an operational need to transit with minimum operator fatigue safely to a pre-defined point and covertly deploy and retrieve SEALS. To meet these operational needs, these platforms require upgra ...

In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...

There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...